Skip to main content

Para mag-trade sa US, pumunta sa polymarket.us

icon for FDA moves BPC-157 to Category 1 by…?
Politika·FDA

FDA moves BPC-157 to Category 1 by…?

icon for FDA moves BPC-157 to Category 1 by…?
Politika·FDA

FDA moves BPC-157 to Category 1 by…?

BAGO
Dec 31, 2026
Polymarket

$4,551 Vol.

Polymarket

December 31, 2026

$2,549 Vol.

53%

This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's Pharmacy Compounding Advisory Committee voted 8-6 with one abstention on July 23, 2026, to recommend adding BPC-157 to the 503A Bulk Drug Substances List, reversing staff concerns over limited clinical data, immunogenicity risks, and adverse event reports. This non-binding step followed the peptide's removal from Category 2 earlier in April 2026 and opens a formal notice-and-comment rulemaking process that historically requires eight to twelve months before any change takes effect. Trader consensus reflects the advisory outcome as progress yet assigns lower near-term probability to swift Category 1 placement, given procedural timelines, committee composition scrutiny, and the FDA's discretion to diverge from panel recommendations. No final agency decision has been announced as of mid-September 2026.

This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.

A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.

Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.

A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.

The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volume
$4,551
Petsa ng Pagtatapos
Jan 1, 2027
Binuksan ang Market
Jun 22, 2026, 10:10 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's Pharmacy Compounding Advisory Committee voted 8-6 with one abstention on July 23, 2026, to recommend adding BPC-157 to the 503A Bulk Drug Substances List, reversing staff concerns over limited clinical data, immunogenicity risks, and adverse event reports. This non-binding step followed the peptide's removal from Category 2 earlier in April 2026 and opens a formal notice-and-comment rulemaking process that historically requires eight to twelve months before any change takes effect. Trader consensus reflects the advisory outcome as progress yet assigns lower near-term probability to swift Category 1 placement, given procedural timelines, committee composition scrutiny, and the FDA's discretion to diverge from panel recommendations. No final agency decision has been announced as of mid-September 2026.

This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.

A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.

Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.

A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.

The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volume
$4,551
Petsa ng Pagtatapos
Jan 1, 2027
Binuksan ang Market
Jun 22, 2026, 10:10 PM ET

Resolver

0x65070BE91...

Kaugnay

icon for Will Heidi Overton be confirmed as FDA Commissioner by December 31?

Will Heidi Overton be confirmed as FDA Commissioner by December 31?

64%
icon for Will Tencent be removed from Chinese Military Companies list by June 30, 2027?

Will Tencent be removed from Chinese Military Companies list by June 30, 2027?

33%
icon for Weed rescheduled by December 31?

Weed rescheduled by December 31?

22%

Mag-ingat sa mga external link.

Mga Madalas na Tanong

Ang "FDA moves BPC-157 to Category 1 by…?" ay isang prediction market sa Polymarket na may 2 posibleng outcomes kung saan bumibili at nagbebenta ang mga trader ng shares batay sa kanilang pinaniniwalaan na mangyayari. Ang kasalukuyang nangunguna ay "December 31, 2026" sa 53%, sinusundan ng "August 31, 2026" sa 0%. Ang mga presyo ay sumasalamin sa real-time crowd-sourced probabilities. Halimbawa, ang isang share na naka-presyo sa 53¢ ay nagpapahiwatig na kolektibong itinatakda ng market ang 53% na tsansa sa outcome na iyon. Patuloy na nagbabago ang mga odds na ito habang tumutugon ang mga trader sa mga bagong development at impormasyon. Ang mga shares sa tamang outcome ay mare-redeem sa $1 bawat isa sa market resolution.

Ang "FDA moves BPC-157 to Category 1 by…?" ay isang bagong likhang market sa Polymarket, inilunsad noong Jun 22, 2026. Bilang isang maagang market, ito ang iyong pagkakataon na maging kabilang sa mga unang trader na magtakda ng odds at mag-establish ng mga paunang price signal ng market. Maaari mo ring i-bookmark ang pahinang ito para subaybayan ang volume at trading activity habang lumalaki ang market sa paglipas ng panahon.

Para mag-trade sa "FDA moves BPC-157 to Category 1 by…?," i-browse ang 2 available na outcomes na nakalista sa pahinang ito. Ang bawat outcome ay may kasalukuyang presyo na kumakatawan sa implied probability ng market. Para kumuha ng posisyon, piliin ang outcome na pinaniniwalaan mong pinaka-malamang, piliin ang "Yes" para mag-trade pabor dito o "No" para mag-trade laban dito, ilagay ang iyong halaga, at i-click ang "Trade." Kung tama ang iyong napiling outcome kapag na-resolve ang market, nagbabayad ang iyong "Yes" shares ng $1 bawat isa. Kung mali, nagbabayad ang mga ito ng $0. Maaari ka ring magbenta ng iyong shares anumang oras bago ang resolution kung gusto mong i-lock in ang kita o bawasan ang pagkalugi.

Ang kasalukuyang frontrunner para sa "FDA moves BPC-157 to Category 1 by…?" ay "December 31, 2026" sa 53%, ibig sabihin itinatakda ng market ang 53% na tsansa sa outcome na iyon. Ang sumunod na pinaka-malapit na outcome ay "August 31, 2026" sa 0%. Nag-a-update ang mga odds na ito sa real-time habang bumibili at nagbebenta ang mga trader ng shares, kaya sinasalamin nila ang pinakabagong kolektibong view kung ano ang pinaka-malamang na mangyari. Bumalik nang madalas o i-bookmark ang pahinang ito para sundan kung paano nagbabago ang odds habang lumilitaw ang bagong impormasyon.

Ang mga resolution rules para sa "FDA moves BPC-157 to Category 1 by…?" ay tiyak na nagde-define kung ano ang kailangang mangyari para sa bawat outcome na maideklara bilang panalo — kasama ang mga opisyal na data source na ginagamit para matukoy ang resulta. Maaari mong i-review ang kumpletong resolution criteria sa "Rules" section sa pahinang ito sa itaas ng mga komento. Inirerekomenda namin na basahin nang mabuti ang mga patakaran bago mag-trade, dahil tinutukoy nila ang mga tiyak na kondisyon, edge cases, at mga source na namamahala kung paano nise-settle ang market na ito.